Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial
Article Abstract:
A monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha MAb) does not appear to reduce the death rate in patients with sepsis syndrome. Sepsis syndrome is a bacterial infection in the bloodstream that can cause low blood pressure, elevated heart rate, rapid breathing, organ malfunction, and death. Researchers infused 664 sepsis patients with either 7.5 or 15 milligrams of TNF-alpha MAb per kilogram of body weight and 330 sepsis patients with a placebo. Septic patients in shock who received TNF-alpha MAb had a significantly lower death rate than placebo-treated septic shock patients at the three-, seven-, and 14-day follow-up. At the 28-day follow-up, the overall death rate was 31.3%, which was similar among patients in all three treatment groups. Serious adverse effects occurred in 4.6% of all patients.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial
Article Abstract:
The p55 tumor necrosis factor receptor appears to reduce mortality rates in patients with septic shock. Septic shock is caused by severe bacterial infections and has a high mortality rate. Researchers tested the p55 tumor necrosis factor receptor in 498 patients by randomly allocating the patients to an infusion of two dosages of the receptor or a placebo. The higher dose significantly reduced mortality rates in those with septic shock. Tumor necrosis factor is believed to be involved in the development of septic shock.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial
Article Abstract:
The drug tifacogin may not benefit patients with sepsis and a high international normalized ratio (INR) value, according to a study of 1,754 patients treated at 245 hospitals in 17 countries in North America, Europe, and Israel. Sepsis is a serious bacterial infection in the blood that can cause multiple organ failure. Tifacogin inhibits a substance that causes blood to clot because abnormal blood clotting is believed to occur during sepsis.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome: A Randomized Controlled Trial
- Abstracts: Effect of estrogen plus progestin on global cognitive function in postmentopausal women: a randomized controlled trial
- Abstracts: Effect of estrogen plus progestin on global cognitive function in postmentopausal women: a randomized controlled trial. part 2
- Abstracts: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial
- Abstracts: Estimating prognosis for nursing home residents with advanced dementia. Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment